AusperBio Secures $73 Million in Series B Financing to Advance Hepatitis B Therapy
Sino-US liver therapy developer AusperBio has announced the completion of a USD 73 million Series...
Advaccine Biotechnology’s MICROEPAD Receives FDA Registration Approval
China-based vaccine developer Advaccine Biotechnology has announced receiving registration approval from the US Food and...
Shandong Buchang Pharmaceuticals Terminates Agreement with NOVAST Laboratories
China-based Shandong Buchang Pharmaceuticals Co., Ltd (SHA: 603858) has announced the termination of the development,...
Chia Tai Tianqing’s Benmelstobart and Anlotinib Combo Meets Primary Endpoint in Phase III Study
China-based Chia Tai Tianqing Pharmaceutical, a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), has announced...
China Isotope & Radiation Corporation’s [18F] Piramide Receives NMPA Clinical Trial Approval
On December 24, 2024, China Isotope & Radiation Corporation (HKG: 1763) announced that its subsidiary,...
Hybio Pharmaceutical Receives US FDA Approval for Biosimilar Victoza (Liraglutide)
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced receiving official approval from the US...
Shanxi C&Y Pharmaceutical Initiates Clinical Study for Generic Ferric Maltol with NMPA Approval
China’s Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254) has announced the initiation of a...
Boji Medical Technology Receives NMPA Approval for TBA Clinical Study in Drug-Resistant Tuberculosis
China-based Clinical Research Organization (CRO) Boji Medical Technology Co., Ltd. (SHE: 300404) has announced receiving...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for Prostate Cancer and Solid Tumor Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Sichuan Biokin’s BL-M08D1 and CSPC’s SYS6010 Eye Breakthrough Therapy Designations in China
The China’s Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Biokin Pharmaceutical...
CDE Indicates Priority Review for Boehringer Ingelheim’s Zongertinib and Peers
The China’s Center for Drug Evaluation (CDE) website has indicated that several drugs, including German...
Zelgen Biopharmaceuticals’ ZG005 Gets NMPA Green Light for Solid Tumor and Lymphoma Clinical Trial
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced receiving clinical approval from the National...
Western Chongqing Southern Sichuan Precision Medicine Center Digital Platform Launches in Rongchang District
On December 24, the Western Chongqing Southern Sichuan Precision Medicine Center Digital Information Platform was...
ProteLight Pharma’s Peceleganan (PL-5) Accepted for Review by China’s CDE
China’s Center for Drug Evaluation (CDE) website has indicated that a market filing by local...
Innovent Biologics Partners with Suzhou ForLong to Explore Sintilimab and FL115 Combination in Solid Tumors
China-based Innovent Biologics, Inc. (HKG: 1801) has announced a clinical study and supply agreement with...
Zhejiang Huahai Pharmaceutical’s Subsidiary Huaota Bio Secures $27.4 Million Investment
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that its macromolecular drug-focused subsidiary, Shanghai...
Bristol-Myers Squibb’s Sotyktu Meets Primary Endpoints in POETYK PsA Studies
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from the pivotal...
Bio-Thera Solutions Enters Licensing Agreement with Tabuk Pharmaceutical for BAT2206 in Saudi Arabia
China-based Bio-Thera Solutions (SHA: 688177) has announced a licensing agreement with Tabuk Pharmaceutical Manufacturing Company,...
Achilles Therapeutics and AstraZeneca Seal $12 Billion Deal for TRACERx NSCLC Study Data
UK-based Achilles Therapeutics plc has announced a landmark deal worth USD 12 billion with AstraZeneca...
Nuvation Bio’s Taletrectinib NDA for ROS1+ NSCLC Receives FDA Priority Review
US-based Nuvation Bio Inc. (NYSE: NUVB) has announced that the New Drug Application (NDA) for...